7 results
Study BP29541 is a first in-human, open-label, multicenter, dose-escalation Phase I clinical study of single-agent RO6958688. The study will be conducted in two parts. Part I of the study is single ascending dose in single patient cohorts to…
Assess the potential efficay of L-serine dietary supplementation in patients children with a GRIN2B LoS mutation.
The aim of this study is to improve clinical outcomes in patients with insulin-treated DM after coronary stent placement in the treatment of coronary artery disease with drug-eluting balloon therapy after stent placement.
1. To determine the change in plaque characteristics of non-culprit LRPs, as measured with IVUS/NIRS, after treatment with DEB in patients with ACS.2. To develop a non-invasive algorithm that is able to detect LRPs with CT.
* to describe the safety profile for qW, q2W and q3W regimens. * to determine the Maximum Tolerated Dose (MTD), if achieved (all regimens)* to describe the pharmacokinetics (PK) of single-agent RO6895882. Substudy BP28920/IMGThe study is designed to…
To determine the change in plaque characteristics after treatment with DEB of additional LRPs, as measured by IVUS / NIRS, in ACS patients.
The primary objective of the study is to evaluate the efficacy of obinutuzumab(GA101) plus venetoclax (GVe) versus standard chemoimmunotherapy (BR/FCR)[concerning MRD negativity measured by flow cytometry in peripheral blood (PB)at month 15] and…